Hinge Health, Inc. (HNGE) Stock Price & How to Invest

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Hinge Health completed its initial public offering on the NYSE in May 2025. The company has positioned itself as the largest digital MSK platform by member coverage in the US. The MSK category is one of the largest cost drivers in employer health benefits (musculoskeletal conditions are among the most expensive conditions for employers), creating strong demand for cost-effective alternatives to surgery and traditional physical therapy. Headquartered in San Francisco, California. Daniel Perez is co-founder and CEO.

Digital health categories are competitive with various platforms targeting MSK and other condition areas. Employer benefits cycle and economic pressure can slow new logo growth. Member engagement determines outcomes and ROI to customers; engagement scaling must continue. Recent IPO creates trading dynamics around lockup expirations and investor sentiment.

15 analysts publish price targets on HNGE, averaging $106.47 against a $90.02 price as of September 2026, or +18.3%. The published targets run from $85.00 to $140.00, a moderate spread, and the ratings split 15 buy, 1 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HNGE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Hinge Health, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Employer benefit penetration. MSK conditions are among the most expensive conditions for employer health benefits. The most optimistic published target, $140.00, assumes this works close to its best case.

The case against. Digital health categories are competitive with various platforms targeting MSK and other condition areas. The most pessimistic target, $85.00, is roughly what HNGE is worth if this bites instead.

Read the full bull and bear case on HNGE, including what would have to change to break either one. Walnut is not an investment adviser.

No. Hinge Health, Inc. (HNGE) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Hinge Health, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$400 million (estimated, post-IPO disclosure)
• Operating margin: Approaching breakeven; varies by quarter
• Net income (TTM): Modest GAAP loss; non-GAAP near breakeven
• EPS (TTM): Near zero
• P/E (TTM): Not meaningful at current earnings
• Price to sales: Premium reflecting digital health growth
• Dividend yield: None
• Free cash flow: Approaching breakeven
• Member coverage: Substantial scale; largest US digital MSK platform

Hinge Health's valuation reflects the digital health growth premium, the demonstrated category leadership in MSK, and the path-to-profitability story. As a recent IPO, valuation is sensitive to broader digital health sector sentiment and to quarterly progression toward profitability.

Other names that sit close to HNGE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HNGE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HNGE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HNGE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Hinge Health (HNGE) is a category-leading digital MSK platform whose thesis rests on employer-benefit penetration, surgery-prevention ROI, and operating leverage as member coverage scales. In a portfolio it behaves as a speculative, volatile digital-health growth holding, sensitive to post-IPO lockup dynamics, member engagement, and the broader digital-health sector mood rather than dividends or stable earnings.

Whether HNGE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HNGE a buy or a sell?, and where the stock could go from here in the HNGE stock forecast.

For income investors, whether HNGE pays a dividend and how the payout looks is covered in does HNGE pay a dividend? And to weigh HNGE against a peer, read the full side-by-side comparisons: HNGE vs BMY and HNGE vs CI.